Drugs

Papers
(The H4-Index of Drugs is 57. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)
ArticleCitations
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression486
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments458
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema359
Teclistamab: First Approval331
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled,233
Epcoritamab: First Approval203
Eftrenonacog Alfa: A Review in Haemophilia B177
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”162
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations157
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using136
Vorasidenib: First Approval134
Targeting DNA Damage Response Deficiency in Thoracic Cancers133
Spesolimab for the Treatment of Generalized Pustular Psoriasis132
Senaparib: First Approval125
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments119
Bimekizumab for the Treatment of Psoriasis115
Aprocitentan: First Approval115
New Therapies on the Horizon for Primary Biliary Cholangitis113
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences108
Cosibelimab: First Approval103
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer103
Lenacapavir: First Approval101
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies100
QT Prolongation and Risk of Death with the Use of Methadone for Chronic Cancer and Noncancer Pain: Myths or Reality?95
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure95
Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial95
Ivarmacitinib Sulfate: First Approval95
Androgenetic Alopecia: Therapy Update94
Drugs in Development to Manage Acute Pain91
Atogepant: First Approval90
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine87
Acoltremon: First Approval86
Olipudase Alfa: First Approval84
Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms84
Repotrectinib: First Approval83
Danicopan: First Approval82
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection79
Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis79
Cancer Pain Treatment Strategies in Patients with Cancer78
Delgocitinib 20 mg/g Cream: A Review in Chronic Hand Eczema77
Olverembatinib: First Approval77
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?76
Mosunetuzumab: First Approval74
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids73
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?73
Mazdutide: First Approval72
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification68
Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections68
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology67
Correction to: Tapinarof Cream 1%: First Approval66
Managing Burning Mouth Syndrome: Current and Future Directions63
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis62
Situational Prevention of Migraine Attacks: Can Early Treatment Change the Conversation?62
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes61
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough59
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer58
Pozelimab: First Approval57
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned57
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options57
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A57
0.96882390975952